HYDROCHLOROTHIAZIDE TABLETS USP, Rx only

/HYDROCHLOROTHIAZIDE TABLETS USP, Rx only
HYDROCHLOROTHIAZIDE TABLETS USP, Rx only2018-09-06T09:12:40+00:00

Prescription Drug Name:

HYDROCHLOROTHIAZIDE TABLETS USP, Rx only

ID:

65d215ee-7a91-2309-e053-2a91aa0add8a

Code:

34391-3

DESCRIPTION


id: 65d21269-8554-1ec6-e053-2a91aa0ab66d
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro-2
H-1,2,4-benzothiadiazine -7-sulfonamide 1,1-dioxide and has the following structural formula:
Hydrochlorothiazide, USP is a white, or practically white, crystalline powder which is slightly soluble in water, freely soluble in sodium hydroxide solution, in
n-butylamine, and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform, and in dilute mineral acids. Each tablet for oral administration contains 25 mg or 50 mg hydrochlorothiazide. In addition, each tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, FD&C yellow #6, D&C yellow #10, colloidal silicon dioxide, sodium starch glycolate, and magnesium stearate; the 50 mg also contains stearic acid.

CLINICAL PHARMACOLOGY


id: 65d21269-8555-1ec6-e053-2a91aa0ab66d
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure. Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.

INDICATIONS AND USAGE


id: 65d21269-8556-1ec6-e053-2a91aa0ab66d
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

CONTRAINDICATIONS


id: 65d21269-8557-1ec6-e053-2a91aa0ab66d
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Anuria. Hypersensitivity to this product or to other sulfonamide-derived drugs.

WARNINGS


id: 65d21269-8558-1ec6-e053-2a91aa0ab66d
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with diuretics (see
PRECAUTIONS, Drug lnteractions ).
Acute Myopia and Secondary Angle-Closure Glaucoma Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

ADVERSE REACTIONS


id: 65d21269-855a-1ec6-e053-2a91aa0ab66d
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Body as a Whole

Weakness. Cardiovascular

Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs). Digestive

Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. Hematologic

Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity

Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura. Metabolic

Electrolyte imbalance (see
PRECAUTIONS ), hyperglycemia, glycosuria, hyperuricemia. Musculoskeletal

Muscle spasm. Nervous System/Psychiatric

Vertigo, paresthesias, dizziness, headache, restlessness. Renal

Renal failure, renal dysfunction, interstitial nephritis (see
WARNINGS ). Skin

Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia. Special Senses

Transient blurred vision, xanthopsia. Urogenital

Impotence. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.

OVERDOSAGE


id: 65d21269-855b-1ec6-e053-2a91aa0ab66d
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD
50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

DOSAGE AND ADMINISTRATION


id: 65d21269-855c-1ec6-e053-2a91aa0ab66d
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.

HOW SUPPLIED


id: 65d217da-eb6c-8080-e053-2991aa0a042e
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Hydrochlorothiazide Tablets USP are available as round, light orange, flat-faced beveled edge, bisected tablets, debossed with LCI on one side and 1413 on the other side, containing 25 mg of hydrochlorothiazide USP, packaged in bottles of 100 (NDC 0527-1413-01) and 1000 (NDC 0527-1413-10) tablets. Hydrochlorothiazide Tablets USP are available as round, light orange, flat-faced beveled edge, bisected tablets, debossed with LCI on one side and 1414 on the other side, containing 50 mg of hydrochlorothiazide USP, packaged in bottles of 100 (NDC 0527-1414-01) and 1000 (NDC 0527-1414-10) tablets. PHARMACIST: Dispense in a well-closed container as defined in the USP. Use child-resistant closure. Store at controlled room temperature 20°-25°C (68°-77°F) (see USP). Manufactured by: LANNETT COMPANY, INC.

Philadelphia, PA 19136 Made in the USA Revised: 07/11, Revision 1 10-537

PRINCIPAL DISPLAY PANEL — 25 mg


id: 65d21269-855e-1ec6-e053-2a91aa0ab66d
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4